Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Viet Nam Pharmaceutical - JSC's Debt-to-EBITDA or its related term are showing as below:
HSTC:DVN'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: 1.76 Med: 3.58 Max: 4.54
Current: 1.81
During the past 7 years, the highest Debt-to-EBITDA Ratio of Viet Nam Pharmaceutical - JSC was 4.54. The lowest was 1.76. And the median was 3.58.
HSTC:DVN's Debt-to-EBITDA is ranked worse than 52.72% of 681
companies
in the Drug Manufacturers industry
Industry Median: 1.62
vs HSTC:DVN: 1.81
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Viet Nam Pharmaceutical - JSC Debt-to-EBITDA Related Terms
Viet Nam Pharmaceutical - JSC Debt-to-EBITDA Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Viet Nam Pharmaceutical - JSC Debt-to-EBITDA Chart
For the Drug Manufacturers - Specialty & Generic subindustry, Viet Nam Pharmaceutical - JSC's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Viet Nam Pharmaceutical - JSC Debt-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Viet Nam Pharmaceutical - JSC's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Viet Nam Pharmaceutical - JSC's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Mar. 2026) EBITDA data.
Viet Nam Pharmaceutical - JSC (HSTC:DVN) has a Debt-to-EBITDA of 2.10 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Viet Nam Pharmaceutical - JSC. This is 41% below median its historical median of 3.58. Over the past decade, Viet Nam Pharmaceutical - JSC's Debt-to-EBITDA has ranged from 1.76 to 4.54. According to the industry distribution chart, Viet Nam Pharmaceutical - JSC ranks #359 out of 681 companies in the Drug Manufacturers industry, placing it in the top 52.7%.
Is Viet Nam Pharmaceutical - JSC's Debt-to-EBITDA too high?
Viet Nam Pharmaceutical - JSC's current Debt-to-EBITDA of 2.10 is 41% below median its 10-year median of 3.58. Over the past 10 years, this metric has ranged from a low of 1.76 to a high of 4.54. The Drug Manufacturers industry median Debt-to-EBITDA is 1.62. Viet Nam Pharmaceutical - JSC's value of 2.10 is 29.6% above this industry median. Based on the distribution chart, Viet Nam Pharmaceutical - JSC ranks #359 out of 681 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Viet Nam Pharmaceutical - JSC has a GF Score™ of 81/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Viet Nam Pharmaceutical - JSC's Debt-to-EBITDA compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Viet Nam Pharmaceutical - JSC ranks #359 out of 681 companies for Debt-to-EBITDA. This places Viet Nam Pharmaceutical - JSC in the lower half of its industry. The industry median Debt-to-EBITDA is 1.62. Viet Nam Pharmaceutical - JSC's value of 2.10 is 29.6% above this benchmark. Historically, Viet Nam Pharmaceutical - JSC's own Debt-to-EBITDA has ranged from 1.76 to 4.54 over the past decade. While the company's 10-year median is 3.58 vs. the industry median of 1.62, Viet Nam Pharmaceutical - JSC has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Drug Manufacturers company?
The median Debt-to-EBITDA among Drug Manufacturers companies is 1.62, based on 681 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Viet Nam Pharmaceutical - JSC's current Debt-to-EBITDA of 2.10 is 29.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Viet Nam Pharmaceutical - JSC. For the Drug Manufacturers industry, the median Debt-to-EBITDA is 1.62 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Viet Nam Pharmaceutical - JSC's current Debt-to-EBITDA is 2.10, which is 41% below median its own 10-year median of 3.58. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Viet Nam Pharmaceutical - JSC stock overvalued right now?
Based on GuruFocus' analysis, Viet Nam Pharmaceutical - JSC (HSTC:DVN) is currently considered Modestly Undervalued. The stock's GF Value™ is ₫22,087.66, compared to a current price of ₫18,200.00 — trading 17.6% below its estimated fair value. The current Debt-to-EBITDA is 2.10, which is 41% below median its 10-year median of 3.58 and 29.6% above the Drug Manufacturers industry median of 1.62. Viet Nam Pharmaceutical - JSC's overall GF Score™ is 81/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Viet Nam Pharmaceutical - JSC (HSTC:DVN), the current Debt-to-EBITDA is 2.10 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Viet Nam Pharmaceutical - JSC (HSTC:DVN) Overvalued in 2026?
Based on GuruFocus' analysis, Viet Nam Pharmaceutical - JSC stock appears to be undervalued.
The current stock price of ₫18,200.00 is trading 17.6% below its estimated GF Value™ of ₫22,087.66.
GuruFocus considers Viet Nam Pharmaceutical - JSC to be Modestly Undervalued.
Key valuation signals for HSTC:DVN:
Debt-to-EBITDA: 2.10 (41% below median its 10-year median of 3.58)
GF Value™: ₫22,087.66 vs. price of ₫18,200.00 (17.6% below fair value)
Industry Position: 29.6% above the Drug Manufacturers median (#359 of 681)
No single metric tells the full story. See the HSTC:DVN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Viet Nam Pharmaceutical Corp - JSC is engaged in the manufacturing of drugs. The company provides testing services for drugs and medicinal ingredients.
81GF Score
Get the complete analysis for HSTC:DVN
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HSTC:DVN has been successfully added to your 
